Abstract:Abstract Mammography screening is widely used for earlier detection of breast cancer and has been shown to contribute to reduction of mortality and morbidity. Most screen-detected breast cancers are early stage, hormonal receptor-positive, HER2-negative (HR+ HER2-) breast cancers. The majority of HR+ HER2- cancers are assigned to molecular intrinsic subtypes of Luminal A and Luminal B, which generally harbour low recurrence risk, with Luminal B cases being more invasive but still less aggressive than HER2-enriched or Basal-like subtypes. However, some of these Luminal cancers later recur (5+ years after diagnosis) often as advanced and/or metastatic disease. We studied a cohort of screen-detected breast cancers (42 cases) at Sunnybrook Health Sciences Centre (Toronto, ON Canada) with integrated cross-platform radiomics, molecular and proteomic analysis in an attempt to better characterise these cancers and their proclivity for late recurrence. Utilising a Nanostring 200-gene assay, the molecular subtypes (PAM50 and MammaTyper-like) and a range of recapitulated clinical prognostic scores (50-Gene, 70-Gene and 21-Gene Risk) were determined for these cancers. While a majority of cases (29 out of 42) were subtyped as Luminal A cancers by PAM50, a fraction (12 out of 29) of these were either subtyped as Luminal B/HER2+ based on MammaTyper-like results, or measured as intermediate to high risk of recurrence based on the 70-Gene or 21-Gene Risk classification. Although discordant results from multi-parametric assays are not uncommon, we postulate that here, discordance could suggest presence of heterogeneous cellular or molecular elements with invasive phenotype that could lead to aggressive transformations in the long run. Differential expression analysis between Luminal A cases with consistent subtyping and low risk prognostication and those with discordant subtyping or prognostication results revealed a panel of genes with significant changes in expression. Further analysis of RNA expression of these genes via Receiver Operating Characteristic (ROC) curve demonstrated that some genes showed high Area Under the Curve (AUC) scores in the classification between the two groups of Luminal A breast cancers, further supporting the existence of distinct molecular phenotypes. Targeted sequencing with Oncomine Comprehensive Assay V3 did not reveal particular mutational patterns between the two Luminal A groups. Nevertheless, radiomic analysis of mammographic images of the cancer, as well as single cell phenotyping of the tumor microenvironment with protein multiplexing will be incorporated to further characterise elements that are phenotypically different, and potentially identify mechanistic drivers contributing to late recurrence in Luminal A cancers. Citation Format: Alison M. Cheung, Dan Wang, Kela Liu, Yutaka Amemiya, Elzbieta Slodkowska, James G. Mainprize, Jane Bayani, Arun Seth, John Bartlett, Martin J. Yaffe. Integrative cross-platform characterisation of mammographic screen-detected breast cancer. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5622.

Integrative Analysis Identifies Two Molecular and Clinical Subsets in Luminal B Breast Cancer

Abstract 5622: Integrative cross-platform characterisation of mammographic screen-detected breast cancer

Classification of Subgroups with Immune Characteristics Based on DNA Methylation in Luminal Breast Cancer

Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups

Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas

Quantification of subtype purity in Luminal A breast cancer predicts clinical characteristics and survival

Immune gene expression profiling reveals heterogeneity in luminal breast tumors

Overexpression of CDC25A, AURKB, and TOP2A Genes Could Be an Important Clue for Luminal A Breast Cancer

Genomic characterization reveals distinct mutational landscapes and therapeutic implications between different molecular subtypes of triple-negative breast cancer

Gene expression comparison between primary aggressive luminal breast cancer and paired axillary and sentinel lymph node metastasis.

Identification of Breast Cancer Subtypes by Integrating Genomic Analysis with the Immune Microenvironment

Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms

Identification of Tumor Microenvironment-Related Prognostic Biomarkers in Luminal Breast Cancer

Molecular features of luminal breast cancer defined through spatial and single‐cell transcriptomics

Comprehensive Landscape of Epigenetic-Dysregulated Lncrnas Reveals a Profound Role of Enhancers in Carcinogenesis in BC Subtypes

Differential Chromatin Accessibility and Transcriptional Dynamics Define Breast Cancer Subtypes and Their Lineages

Molecular portraits and trastuzumab responsiveness of estrogen receptor-positive, progesterone receptor-positive, and HER2-positive breast cancer.

DNA methylation profiling deciphers three EMT subtypes with distinct prognoses and therapeutic vulnerabilities in breast cancer

Clinical implications of the intrinsic molecular subtypes of breast cancer

Identification of molecular subtypes based on liquid–liquid phase separation and cross-talk with immunological phenotype in bladder cancer

Precision treatment exploration of breast cancer based on heterogeneity analysis of lncRNAs at the single-cell level